



Portland  
Investment Counsel®  
Buy. Hold. And Prosper.®

# ONCOBETA INVESTMENT LP SPOTLIGHT

## NEWS UPDATE

**OncoBeta® GmbH (OncoBeta)** – On May 18th, 2023, OncoBeta and GenesisCare announced a partnership to provide OncoBeta's innovative, non-invasive, single-session treatment for non-melanoma skin cancer. This collaboration will offer access to OncoBeta's treatment option where the current standard of care in Australia consists of surgical treatments that can be painful and scarring.

This partnership will allow OncoBeta to reach more patients in key markets like Australia, where the incidence of non-melanoma skin cancer is highest in the world. Recent data indicates that 70% of Australians will have at least one non-melanoma skin cancer removed and 32% of Australians are treated for non-melanoma skin cancer each year.

### **About OncoBeta® GmbH**

OncoBeta, headquartered in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies. Since its foundation, OncoBeta has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancer. OncoBeta has improved the customized application and device management system in conformity with all health, safety and environmental protection regulatory standards.

### **About GenesisCare**

GenesisCare is one of the largest providers of cancer and cardiac care services in Australia, and have cancer treatment centers in the United States, United Kingdom, and Spain. GenesisCare provides radiotherapy – a vital treatment option for cancer patients – and provides patients with access to diagnostics, medical oncology, surgical oncology, and novel therapies alongside the ability to participate in the latest clinical trials. Headquartered in Australia, GenesisCare clinical teams see more than 450,000 people across 350+ locations, including more than 300 locations in the U.S., 40 in Australia, 14 in the UK, and 18 in Spain.

Please see the press release for further details:

<https://www.digitaljournal.com/pr/news/pr-zen/genescare-and-oncobeta-announce-partnership-to-provide-innovative-treatment-for-non-melanoma-skin-cancer>

OncoBeta is a holding in the OncoBeta Investment LP, for details visit:

[https://www.portlandic.com/OncoBeta\\_Investment\\_LP](https://www.portlandic.com/OncoBeta_Investment_LP)



---

The Partnership is closed to new investments. The Partnership is not publicly offered. OncoBeta International and OncoBeta are not a financial services advisor or provide any professional investment opinions.

This document is confidential and for the use of investors, potential investors and investment dealers only. The contents are not to be communicated, reproduced or distributed to the public or the press.

The News Update is not an offer to sell or a solicitation of an offer to buy a security. The securities discussed in the News Update may not be eligible for sale in some jurisdictions. Certain statements included in this document constitute forward-looking statements, including those identified by the expressions 'anticipate,' 'believe,' 'plan,' 'estimate,' 'expect,' 'intend' and similar expressions to the extent they relate to a security. The forward-looking statements are not historical facts, but reflect the Portfolio Management team's current expectations regarding future results or events. These forward looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. The Portfolio Management team has no specific intention of updating any forward-looking statements whether as a result of new information, future events or otherwise. The views expressed by any external links and subsequent media, including but not limited to videos, are not necessarily those of Portland Investment Counsel Inc. and are provided for general information purposes only. Portland Investment Counsel Inc. assumes no responsibility for the information provided by external sources.

Commissions, management fees and expenses may be associated with investments. Information presented in these materials should be considered for background information only and should not be construed as investment or financial advice. Please consult a Financial Advisor. All information in these materials is subject to modification from time to time without notice.

The amount of risk associated with any particular investment depends largely on your own personal circumstances including your time horizon, liquidity needs, portfolio size, income, investment knowledge and attitude toward price fluctuations. Investors should consult their financial advisor before making a decision as to whether this Fund is a suitable investment for them.

Consent is required for any reproduction, in whole or in part, of this piece and/or of its images and concepts. Please read the Prospectus before investing. PORTLAND INVESTMENT COUNSEL is a registered trademark of Portland Holdings Inc. The Unicorn Design is a trademark of Portland Holdings Inc. Used under license by Portland Investment Counsel Inc. BUY. HOLD. AND PROSPER. is a registered trademark of AIC Global Holdings Inc. used under license by Portland Investment Counsel Inc.

Portland Investment Counsel Inc., 1375 Kerns Road, Suite 100, Burlington, Ontario L7P 4V7 Tel: 1-888-710-4242 • Fax: 905-319-4939 • [www.portlandic.com](http://www.portlandic.com) • [info@portlandic.com](mailto:info@portlandic.com)